Compare Page
Ipamorelin vs MK-677
Quick verdict: Ipamorelin vs MK-677 compares two GH-axis compounds that target the same receptor (GHS-R1a) but differ dramatically in pharmacology. Ipamorelin is an injectable peptide with exceptional selectivity — it stimulates GH without elevating cortisol, ACTH, prolactin, or significantly stimulating appetite.[1] MK-677 (ibutamoren) is a non-peptide, orally bioavailable GHS-R1a agonist with a ~24-hour half-life that provides sustained GH/IGF-1 elevation but with less selectivity — it increases appetite, can affect insulin sensitivity, and produces a broader hormonal response.[2][3] The practical choice hinges on route of administration (oral vs injectable), selectivity requirements, and whether sustained or pulsatile GH elevation better matches the research question.
Read the full peptide profiles: Ipamorelin. (Note: MK-677 does not have a dedicated profile page on this site.)
At a Glance: Ipamorelin vs MK-677
How They Work
Ipamorelin and MK-677 both target the same receptor — GHS-R1a, the ghrelin receptor — but they are fundamentally different molecules. Ipamorelin is a synthetic pentapeptide: a small protein chain that must be administered by injection because peptides are broken down in the digestive tract. Its short half-life (~2 hours) produces discrete GH pulses that closely mimic the body’s natural pulsatile secretory pattern. Raun et al. (1998) established ipamorelin’s unique selectivity: it stimulates GH without elevating cortisol, ACTH, prolactin, or aldosterone — a selectivity profile unmatched by any other GHS-R1a agonist.[1]
MK-677 (ibutamoren) is a non-peptide small molecule with oral bioavailability — it survives digestion and is absorbed through the gut. Its ~24-hour half-life provides sustained, continuous GH/IGF-1 elevation rather than discrete pulses. Nass et al. (2008) demonstrated that 2 years of MK-677 treatment in healthy older adults increased GH and IGF-1 levels to young-adult ranges. However, MK-677 also increased appetite, produced mild cortisol elevation, and affected fasting glucose and insulin sensitivity in some subjects.[2] Chapman et al. (1996) established the pharmacological profile in an early human study.[3]
The pharmacological distinction is significant. Ipamorelin’s short half-life produces pulsatile GH — considered physiologically optimal because the body’s endogenous GH secretion is naturally pulsatile. MK-677’s long half-life produces sustained elevation — potentially more convenient (one daily oral dose vs multiple injections) but less physiologically mimetic. The selectivity gap is also meaningful: ipamorelin is clean; MK-677 has broader receptor cross-talk including appetite stimulation and metabolic effects.
Evidence Comparison
MK-677 has deeper human evidence than ipamorelin, primarily from longer-duration clinical studies. Nass et al. (2008) conducted a 2-year randomised, double-blind, placebo-controlled trial in healthy older adults, demonstrating sustained GH/IGF-1 increases to young-adult ranges — but also documenting effects on glucose metabolism and appetite.[2] Chapman et al. (1996) published the initial human pharmacological characterisation.[3] Murphy et al. (1998) demonstrated effects on body composition in obese subjects, showing increased fat-free mass with MK-677 treatment.[4]
Ipamorelin’s human evidence is more limited but pharmacologically distinctive. The Raun (1998) selectivity study is foundational.[1] Bone health data (Johansen 1999, Andersen 2001) demonstrates GH-mediated skeletal effects in animal models. The Sigalos & Pastuszak (2018) review supports class-level safety.[5] However, long-duration human outcome trials comparable to MK-677’s 2-year data are not available for ipamorelin.
The trade-off: MK-677 has more clinical outcome data (body composition, IGF-1 sustainability, glucose effects), while ipamorelin has a unique pharmacological selectivity profile that no other GHS-R1a agonist can claim. Neither has FDA approval.
When Each Fits Better
Ipamorelin may be the stronger fit when:
- Hormonal selectivity is critical — no cortisol, ACTH, prolactin, or appetite effects[1]
- Pulsatile GH release is desired — more physiologically mimetic than continuous elevation
- Bedtime/sleep research contexts — no cortisol elevation or appetite stimulation to disrupt sleep
- Combination with GHRH analogs is planned — dual-pathway approach with clean GHS-R1a input
MK-677 may be of greater interest when:
- Oral administration is required or preferred — no injection needed[2][3]
- Sustained GH/IGF-1 elevation is the endpoint — ~24-hour duration per dose
- Long-term GH-axis support is being studied — 2-year human data available[2]
- Appetite stimulation is a desired effect — relevant for caloric surplus contexts[3]
Head-to-Head
No direct head-to-head trial comparing ipamorelin and MK-677 exists. The comparison is complicated by the fundamentally different pharmacokinetics: ipamorelin produces short, selective GH pulses while MK-677 produces continuous, less selective GH/IGF-1 elevation. These are not equivalent approaches to GH-axis stimulation — they represent different philosophies (pulsatile vs sustained, selective vs broad).
The insulin sensitivity concern with MK-677 is clinically relevant. Nass et al. (2008) documented that while MK-677 successfully raised GH/IGF-1 to young-adult levels over 2 years, it also increased fasting glucose in some subjects — a meaningful consideration for metabolic safety.[2] Ipamorelin has not shown this effect, likely because its short half-life produces discrete GH pulses rather than sustained elevation, allowing more physiological recovery between pulses.
For researchers evaluating GH-axis support options, the practical framework is: ipamorelin for selective, pulsatile GH stimulation with minimal side effects; MK-677 for convenient oral dosing with sustained IGF-1 elevation but greater metabolic monitoring requirements. For ipamorelin compared to other injectable secretagogues, see GHRP-2 vs Ipamorelin.
FAQ
Is MK-677 a peptide?
No. MK-677 (ibutamoren) is a non-peptide small molecule that mimics ghrelin’s action at the GHS-R1a receptor. Unlike peptides such as ipamorelin, it survives digestion and can be taken orally. It is sometimes grouped with GH secretagogue peptides because it targets the same receptor, but it is chemically distinct.[2][3]
Which produces more growth hormone?
The comparison is not straightforward because they produce different GH patterns. MK-677 produces sustained GH/IGF-1 elevation over 24 hours, resulting in higher total GH exposure per day. Ipamorelin produces more intense but shorter GH pulses. Whether total GH exposure or pulse pattern is more important for downstream effects depends on the specific research question.[1][2]
Does MK-677 affect insulin sensitivity?
Yes. The 2-year Nass et al. study documented that MK-677 increased fasting glucose in some older adult subjects, suggesting an impact on insulin sensitivity.[2] This is consistent with sustained GH elevation’s known insulin-antagonistic effects. Ipamorelin’s pulsatile pattern may avoid this issue, but direct comparison data is not available.
Can MK-677 and ipamorelin be used together?
Both target the same receptor (GHS-R1a), so combining them would likely produce overlapping rather than complementary pharmacology. Unlike combining a GHS-R1a agonist with a GHRH-pathway compound (which uses independent receptor systems), combining two GHS-R1a agonists lacks a clear synergy rationale.
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822.
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. PMID: 18981485.
- Chapman IM, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677). J Clin Endocrinol Metab. 1996;81(12):4249-4257. PMID: 9349662.
- Murphy MG, et al. Effect of alendronate and MK-677, a growth hormone secretagogue, on body composition in elderly women. J Clin Endocrinol Metab. 2001;86(4):1116-1125. PMID: 9467534.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207.